Clinical Trial Update: Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating once-daily long-acting muscarinic antagonists for preventing COPD exacerbations requiring hospitalization or death has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Exacerbation of Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Conditions: COPD Exacerbation | Phase 4 | Status: COMPLETED